

CELGENE CORP /DE/  
Form 8-K  
March 29, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 29, 2019**

**CELGENE CORPORATION**

**(Exact name of registrant as specified in its charter)**

(Address of principal executive offices) (Zip Code)

**(Former name or former address, if changed since last report.)**

“Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Emerging growth company "

2

Exchange Act. "

**ITEM 8.01 OTHER EVENTS.**

On March 29, 2019, Celgene Corporation (“*Celgene*”) announced the settlement of litigation with Lotus Pharmaceutical Co., Ltd. and Alvogen Pine Brook, LLC relating to patents for REVLIMID® (lenalidomide).

Attached hereto and incorporated herein by reference as Exhibit 99.1 is the press release.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

d) Exhibits

99.1 Press Release dated March 29, 2019

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: March 29, 2019 By: /s/ David V. Elkins  
David V. Elkins  
Executive Vice President  
Chief Financial Officer  
(principal financial and accounting officer)